Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants
NCT06905652Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1 trial of R-MDMA and s-3,4-methylenedioxymethamphetamine in post-traumatic stress disorder (PTSD) (3 arms), sponsored by University Hospital Basel. Primary endpoint: Subjective effects at 18 months. Started Jul 2025; status: completed.
02
Drugs
R-MDMAs-3,4-methylenedioxymethamphetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06905652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06905652.